Shine-on Biomedical Co., Ltd.

This early-stage trial is testing a new three-target antibody called SOA101 in people with advanced solid tumors that have stopped responding to standard treatments. The study will first determine safe dosage levels, then look for initial signs that the treatment might help contr…

This is a very early, first-in-human study to check if a new type of drug called SOB100 is safe and how it moves through the body. SOB100 uses tiny natural particles called exosomes, designed to target a specific protein. The study will enroll 15 healthy volunteers to receive inc…